<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Thromb J</journal-id><journal-id journal-id-type="iso-abbrev">Thromb J</journal-id><journal-title-group><journal-title>Thrombosis Journal</journal-title></journal-title-group><issn pub-type="epub">1477-9560</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24341332</article-id><article-id pub-id-type="pmc">3896794</article-id><article-id pub-id-type="publisher-id">1477-9560-11-25</article-id><article-id pub-id-type="doi">10.1186/1477-9560-11-25</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Clinical Investigation</subject></subj-group></article-categories><title-group><article-title>Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Wang</surname><given-names>Yuqi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>submission2010@live.co.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Wang</surname><given-names>Chen</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>cyh-birm@263.net</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Chen</surname><given-names>Zhong</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>chenzhong8658@vip.sina.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Zhang</surname><given-names>Jiwei</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>zhangjiwei001@sina.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Liu</surname><given-names>Zhihong</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>liuzhihong_fw@263.net</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Jin</surname><given-names>Bi</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>jinbi@yahoo.cn</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Ying</surname><given-names>Kejing</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>yingsrrsh@163.com</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Liu</surname><given-names>Changwei</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>submission2010@live.co.uk</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Shao</surname><given-names>Yuxia</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>shaoyuxia45@163.com</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Jing</surname><given-names>Zhicheng</given-names></name><xref ref-type="aff" rid="I10">10</xref><xref ref-type="aff" rid="I11">11</xref><email>submission2010@live.co.uk</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Meng</surname><given-names>Isabelle Ling</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>isabelle.meng@bayer.com</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Prins</surname><given-names>Martin H</given-names></name><xref ref-type="aff" rid="I13">13</xref><email>mh.prins@maastrichtuniversity.nl</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Pap</surname><given-names>&#x000c1;kos F</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>akos.ferenc.pap@bayer.com</email></contrib><contrib contrib-type="author" id="A14"><name><surname>M&#x000fc;ller</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>katharina.mueller@bayer.com</email></contrib><contrib contrib-type="author" corresp="yes" id="A15"><name><surname>Lensing</surname><given-names>Anthonie WA</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>anthonie.lensing@bayer.com</email></contrib><on-behalf-of>the Chinese EINSTEIN Investigators<xref ref-type="corresp" rid="d33e144"/></on-behalf-of></contrib-group><aff id="I1"><label>1</label>Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China</aff><aff id="I2"><label>2</label>Beijing Institute of Respiratory Medicine Beijing Chaoyang Hospital, Beijing, China</aff><aff id="I3"><label>3</label>Department of Vascular Surgery Beijing Anzhen Hospital, Beijing, China</aff><aff id="I4"><label>4</label>Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China</aff><aff id="I5"><label>5</label>Department of Cardiology, Cardiovascular Institute &#x00026; Fu Wai Hospital, Beijing, China</aff><aff id="I6"><label>6</label>Department of Surgery Wuhan Union Hospital, Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</aff><aff id="I7"><label>7</label>Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Affiliated with School of Medicine, Zhejiang University, Hangzhou, China</aff><aff id="I8"><label>8</label>Department of General Surgery, Peking Union Medical College Hospital, Beijing, China</aff><aff id="I9"><label>9</label>Department of Respiratory Medicine, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China</aff><aff id="I10"><label>10</label>Department of Pulmonary Circulation, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China</aff><aff id="I11"><label>11</label>Thrombosis and Vascular Medicine Center, State Key Lab of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China</aff><aff id="I12"><label>12</label>Bayer HealthCare, Berlin, Germany</aff><aff id="I13"><label>13</label>Maastricht University, Maastricht, The Netherlands</aff><aff id="I14"><label>14</label>Bayer HealthCare, Aprather Weg 18a, Wuppertal D-42096, Germany</aff><author-notes><corresp id="d33e144">the Chinese EINSTEIN Investigators</corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2013</year></pub-date><volume>11</volume><fpage>25</fpage><lpage>25</lpage><history><date date-type="received"><day>20</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>8</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Wang et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Wang et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.thrombosisjournal.com/content/11/1/25"/><abstract><sec><title>Background</title><p>The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, included patients in China. This analysis evaluates the results of these studies in this subgroup of patients.</p></sec><sec><title>Methods</title><p>A total of 439 Chinese patients who had acute symptomatic DVT (n=211), or PE with or without DVT (n=228), were randomized to receive rivaroxaban (15&#x000a0;mg twice daily for 21&#x000a0;days, followed by 20&#x000a0;mg once daily) or standard therapy of enoxaparin overlapping with and followed by an adjusted-dose vitamin K antagonist, for 3, 6, or 12&#x000a0;months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or non-major clinically relevant bleeding.</p></sec><sec><title>Results</title><p>The primary efficacy outcome occurred in seven (3.2%) of the 220 patients in the rivaroxaban group and in seven (3.2%) of the 219 patients in the standard-therapy group (hazard ratio, 1.04; 95% confidence interval 0.36&#x02013;3.0; p=0.94). The principal safety outcome occurred in 13 (5.9%) patients in the rivaroxaban group and in 20 (9.2%) patients in the standard-therapy group (hazard ratio, 0.63; 95% confidence interval 0.31&#x02013;1.26; p=0.19). Major bleeding was observed in no patients in the rivaroxaban group and in five (2.3%) patients in the standard-therapy group. In fragile patients (defined as age &#x0003e;75 years, creatinine clearance &#x0003c;50 mL/min, and/or body weight &#x02264;50 kg), the principal safety outcome occurred in four (8.9%) of the 45 patients who received rivaroxaban compared with seven (15.2%) of the 46 patients who received standard therapy.</p></sec><sec><title>Conclusions</title><p>In Chinese patients with acute symptomatic DVT and/or PE, rivaroxaban was as efficacious as enoxaparin followed by vitamin K antagonist therapy, with a similar safety profile. The relative efficacy and safety of rivaroxaban compared with enoxaparin/vitamin K antagonist were consistent with that found in the rest of the world.</p></sec><sec><title>Trial registration number</title><p>EINSTEIN PE, ClinicalTrials.gov
<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT00439777">NCT00439777</ext-link>; EINSTEIN DVT, ClinicalTrials.gov
<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT00440193">NCT00440193</ext-link></p></sec></abstract><kwd-group><kwd>Rivaroxaban</kwd><kwd>Deep vein thrombosis</kwd><kwd>Pulmonary embolism</kwd><kwd>Venous thromboembolism</kwd><kwd>Vitamin K antagonist</kwd><kwd>Randomized trial</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Acute venous thromboembolism (VTE; i.e. deep-vein thrombosis [DVT] or pulmonary embolism [PE]) is a common disorder with an annual incidence in the Western world of approximately 1&#x02013;2 cases per 1000 persons in the general population
[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Short-term treatment of VTE is effective and reduces the risk of recurrent disease, which is the major complication, from an estimated 25% to approximately 3% during the first 6&#x02013;12&#x000a0;months of therapy
[<xref ref-type="bibr" rid="B3">3</xref>]. However, the risk of recurrent VTE remains after treatment ends and can reach 5&#x02013;10% during the first year
[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Although the incidence of VTE in China is not known, the disease is increasingly being recognized by the Chinese healthcare system; this trend may arise as a result of increasing physician attention and the availability of minimally invasive and non-invasive diagnostic tools. The results of VTE treatment among Chinese nationals are not well documented, although there seems to be a general belief that the risk of bleeding is high among patients receiving standard treatment, and that vitamin K antagonist (VKA) therapy should be dosed carefully with a tendency towards lower international normalized ratio (INR) values. Similar concerns about bleeding would also apply to the direct oral anticoagulants.</p><p>Rivaroxaban is an orally active, direct Factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics and pharmacodynamics
[<xref ref-type="bibr" rid="B6">6</xref>], which does not require routine coagulation monitoring, has no food interactions, and has limited drug interactions. These properties have also been confirmed through a rivaroxaban dose escalation study in healthy, elderly Chinese subjects
[<xref ref-type="bibr" rid="B7">7</xref>]. The EINSTEIN DVT and EINSTEIN PE studies evaluated rivaroxaban for the treatment of VTE. In this large, international, phase III clinical program in more than 8000 patients with acute symptomatic DVT and/or PE, monotherapy with rivaroxaban was shown to be as effective as dual-drug therapy with enoxaparin overlapping with and followed by VKA therapy, with reduced occurrence of major bleeding
[<xref ref-type="bibr" rid="B8">8</xref>]&#x02013;
[<xref ref-type="bibr" rid="B11">11</xref>]. In these studies, for the first time, Chinese hospitals participated using the same rivaroxaban regimen.</p><p>Here, we report the results of the 439 patients who participated in the EINSTEIN DVT and EINSTEIN PE studies in China.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>EINSTEIN DVT and EINSTEIN PE were randomized, open-label studies that compared the efficacy and safety of rivaroxaban with standard therapy, consisting of enoxaparin and adjusted-dose VKA, in patients with acute, symptomatic DVT and/or PE
[<xref ref-type="bibr" rid="B8">8</xref>]&#x02013;
[<xref ref-type="bibr" rid="B11">11</xref>]. Patients were eligible if they were of legal age and had objectively confirmed acute, symptomatic DVT and/or PE. Briefly, patients were ineligible to participate if they had received a therapeutic dose of parenteral anticoagulant for more than 48&#x000a0;hours or if they had received more than a single dose of a VKA before randomization; if thrombectomy had been performed, a vena cava filter placed, or a fibrinolytic agent administered for treatment of the current episode; or if they had any contraindication listed in the local labeling of enoxaparin, warfarin, or acenocoumarol. Other criteria for ineligibility were, another indication for a VKA; creatinine clearance (CrCl) &#x0003c;30 mL/min; clinically significant liver disease; active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; childbearing potential without proper contraceptive measures; pregnancy or breast-feeding; or a life expectancy of less than 3&#x000a0;months. Because the metabolism of rivaroxaban is mediated by cytochrome P450 3A4 (CYP3A4), CYP3A4 inhibitors can decrease the metabolism of rivaroxaban, causing an increase in the area under the plasma concentration&#x02013;time curve (AUC) and the maximum plasma concentration (C<sub>max</sub>); conversely, CYP3A4 inducers can increase the metabolism of rivaroxaban, thus decreasing the AUC and C<sub>max</sub>. Therefore, patients requiring concomitant therapy of a strong inhibitor or inducer of CYP3A4 were also ineligible.</p></sec><sec><title>Randomization and treatment regimens</title><p>Randomization was performed with the use of a computerized voice-response system and was stratified according to country and the intended treatment duration (3, 6, or 12&#x000a0;months). The intended duration of treatment was determined by the treating physician before randomization. Patients who were assigned to the rivaroxaban group were given 15&#x000a0;mg twice daily for the first 21&#x000a0;days, followed by 20&#x000a0;mg once daily. Patients who were assigned to the standard-therapy group received enoxaparin at a dose of 1.0&#x000a0;mg/kg of body weight twice daily, and either warfarin or acenocoumarol started within 48&#x000a0;hours after randomization. Enoxaparin was discontinued when the INR was &#x02265;2.0 for 2 consecutive days and the patient had received at least 5&#x000a0;days of enoxaparin treatment. The dose of the VKA was adjusted to maintain an INR of 2.0&#x02013;3.0. The INR was determined at least once a month. The use of non-steroidal anti-inflammatory drugs and antiplatelet agents was discouraged. Aspirin administered at a dose of no more than 100&#x000a0;mg per day, clopidogrel at a dose of 75&#x000a0;mg per day, or both, were permitted.</p></sec><sec><title>Surveillance and follow-up</title><p>Patients were followed for the intended treatment period and were assessed at fixed intervals, which were identical for both treatment arms, using a checklist to elicit information on symptoms and signs of recurrent VTE, bleeding, and adverse events. Patients were instructed to report to the study center immediately if any of these symptoms or signs occurred. In the case of suspected VTE, the protocol required objective testing.</p></sec><sec><title>Outcome assessment</title><p>The primary efficacy outcome was symptomatic recurrent VTE, which was defined as a composite of fatal and non-fatal PE or DVT on the basis of criteria that have been described previously. Death was classified as being due to PE, bleeding, or other established diagnoses. PE was considered the cause of death if there was objective documentation of the condition, or if death could not be attributed to a documented cause and PE could not be confidently ruled out. The principal safety outcome was clinically relevant bleeding, which was defined as a composite of major and clinically relevant non-major bleeding, as described previously
[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Bleeding was defined as major if it was clinically overt and: a) associated with a decrease in hemoglobin level of &#x02265;2.0&#x000a0;g/dL; b) led to the transfusion of &#x02265;2 units of red cells; c) was intracranial or retroperitoneal, or occurred in another critical site; or d) contributed to death. Clinically relevant non-major bleeding was defined as overt bleeding that did not meet the criteria for major bleeding, but was associated with medical intervention, unscheduled contact with a physician, interruption or discontinuation of a study drug, or discomfort or impairment of activities of daily life. Predefined secondary outcomes included major bleeding, death from any cause, vascular events (acute coronary syndrome, ischemic stroke, transient ischemic attack, or systemic embolism), and net clinical benefit (which was defined as a composite of the primary efficacy outcome and major bleeding, as assessed in the intention-to-treat population). All suspected outcome events were classified by a central adjudication committee whose members were unaware of the treatment assignments.</p></sec><sec><title>Statistical analysis</title><p>The primary efficacy analysis was performed on an intention-to-treat basis with the use of a Cox proportional-hazards model stratified according to the intended duration of treatment and index event (DVT/PE), with adjustment for the presence or absence of cancer at baseline. The population for the safety analysis was defined as all patients who received at least one dose of a study drug. Bleeding events were included in the analysis if they occurred during treatment or within 2&#x000a0;days after the last dose of a study drug. Kaplan&#x02013;Meier curves were generated to display the distribution of bleeding over time. In addition, analyses of the principal safety outcome in prespecified subgroups were performed. The mean time during which the INR was within the therapeutic range was calculated after the discontinuation of enoxaparin, with correction for interruptions in the administration of VKAs.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patients</title><p>From May 2008 through to March 2011, 439 patients were enrolled at 21 sites in China (details of investigators and sites are listed in Additional file
<xref ref-type="supplementary-material" rid="S1">1</xref>) 211 patients had DVT only and 228 had PE with (n=67) or without DVT (n=161). A total of 220 patients were assigned to receive rivaroxaban, and 219 were assigned to receive enoxaparin and a VKA (standard therapy). The characteristics of patients were similar at baseline in the rivaroxaban and standard-therapy groups (Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>). One patient in each treatment arm did not receive the assigned study treatment.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic and clinical characteristics: Chinese patients in the EINSTEIN DVT and EINSTEIN PE studies*</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Characteristic</bold></th><th align="center"><bold>Rivaroxaban (n=220)</bold></th><th align="center"><bold>Standard therapy (n=219)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><italic>Mean age, years</italic><hr/></td><td align="center" valign="bottom">58.6 &#x000b1; 15.8<hr/></td><td align="center" valign="bottom">59.0 &#x000b1; 15.0<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Male sex, n (%)</italic><hr/></td><td align="center" valign="bottom">127 (57.7)<hr/></td><td align="center" valign="bottom">112 (51.1)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Weight, n (%)</italic><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02264;50 kg<hr/></td><td align="center" valign="bottom">11 (5.0)<hr/></td><td align="center" valign="bottom">15 (6.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x0003e;50&#x02013;80&#x000a0;kg<hr/></td><td align="center" valign="bottom">182 (82.7)<hr/></td><td align="center" valign="bottom">188 (85.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x0003e;80 kg<hr/></td><td align="center" valign="bottom">25 (11.4)<hr/></td><td align="center" valign="bottom">16 (7.3)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Missing data<hr/></td><td align="center" valign="bottom">2 (0.9)<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Creatinine clearance, n (%)</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x0003c;30 mL/min<hr/></td><td align="center" valign="bottom">1 (0.5)<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;30&#x02013;&#x0003c;50 mL/min<hr/></td><td align="center" valign="bottom">19 (8.6)<hr/></td><td align="center" valign="bottom">28 (12.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;50&#x02013;&#x0003c;80 mL/min<hr/></td><td align="center" valign="bottom">75 (34.1)<hr/></td><td align="center" valign="bottom">72 (32.9)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02265;80 mL/min<hr/></td><td align="center" valign="bottom">117 (53.2)<hr/></td><td align="center" valign="bottom">116 (53.0)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Missing data<hr/></td><td align="center" valign="bottom">8 (3.6)<hr/></td><td align="center" valign="bottom">3 (1.4)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Diagnostic method, PE cohort, n (%)</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Spiral computed tomography<hr/></td><td align="center" valign="bottom">99 (86.8)<hr/></td><td align="center" valign="bottom">102 (87.9)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Ventilation&#x02013;perfusion lung scanning<hr/></td><td align="center" valign="bottom">11 (9.6)<hr/></td><td align="center" valign="bottom">10 (8.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Pulmonary angiography<hr/></td><td align="center" valign="bottom">3 (2.6)<hr/></td><td align="center" valign="bottom">1 (0.9)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Not confirmed/not evaluable<hr/></td><td align="center" valign="bottom">1 (0.9)<hr/></td><td align="center" valign="bottom">3 (2.6)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Anatomical extent of PE, n (%)</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Limited: &#x02264;25% of vasculature of a single lobe<hr/></td><td align="center" valign="bottom">13 (11.4)<hr/></td><td align="center" valign="bottom">10 (8.6)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Intermediate<hr/></td><td align="center" valign="bottom">67 (58.8)<hr/></td><td align="center" valign="bottom">73 (62.9)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Extensive: multiple lobes and &#x0003e;25% of entire pulmonary vasculature<hr/></td><td align="center" valign="bottom">30 (26.3)<hr/></td><td align="center" valign="bottom">29 (25.0)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Not assessable<hr/></td><td align="center" valign="bottom">4 (3.5)<hr/></td><td align="center" valign="bottom">4 (3.4)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Diagnostic method, DVT cohort, n (%)</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Ultrasonography<hr/></td><td align="center" valign="bottom">130 (90.9)<hr/></td><td align="center" valign="bottom">120 (89.6)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Venography<hr/></td><td align="center" valign="bottom">1 (0.7)<hr/></td><td align="center" valign="bottom">3 (2.2)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Computed tomography scan<hr/></td><td align="center" valign="bottom">4 (2.8)<hr/></td><td align="center" valign="bottom">1 (0.7)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Not confirmed/not evaluable<hr/></td><td align="center" valign="bottom">6 (4.2)<hr/></td><td align="center" valign="bottom">9 (6.7)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Anatomical extent of proximal DVT, n (%)</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Limited (popliteal vein or more distal)<hr/></td><td align="center" valign="bottom">25 (17.5)<hr/></td><td align="center" valign="bottom">17 (12.7)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Intermediate (most proximal: superficial femoral vein)<hr/></td><td align="center" valign="bottom">25 (17.5)<hr/></td><td align="center" valign="bottom">27 (20.1)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Extensive (most proximal: common femoral or iliac vein)<hr/></td><td align="center" valign="bottom">112 (78.3)<hr/></td><td align="center" valign="bottom">108 (80.6)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Time from onset of symptoms to randomization, days</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Median<hr/></td><td align="center" valign="bottom">9.0<hr/></td><td align="center" valign="bottom">9.0<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Interquartile range<hr/></td><td align="center" valign="bottom">4.0&#x02013;19.0<hr/></td><td align="center" valign="bottom">4.0&#x02013;20.0<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Cause of DVT or PE, n (%)</italic><sup>
<italic>&#x02020;</italic>
</sup><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Unprovoked<hr/></td><td align="center" valign="bottom">164 (74.5)<hr/></td><td align="center" valign="bottom">162 (74.0)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Secondary DVT or PE<hr/></td><td align="center" valign="bottom">56 (25.5)<hr/></td><td align="center" valign="bottom">57 (26.0)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Recent surgery or trauma<hr/></td><td align="center" valign="bottom">34 (15.5)<hr/></td><td align="center" valign="bottom">39 (17.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Immobilization<hr/></td><td align="center" valign="bottom">21 (9.5)<hr/></td><td align="center" valign="bottom">24 (11.0)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Estrogen therapy<hr/></td><td align="center" valign="bottom">2 (0.9)<hr/></td><td align="center" valign="bottom">4 (1.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Active cancer<hr/></td><td align="center" valign="bottom">6 (2.7)<hr/></td><td align="center" valign="bottom">7 (3.2)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Puerperium<hr/></td><td align="center" valign="bottom">2 (0.9)<hr/></td><td align="center" valign="bottom">4 (1.8)<hr/></td></tr><tr><td align="left">&#x02003;Previous DVT or PE</td><td align="center">27 (12.3)</td><td align="center">36 (16.4)</td></tr></tbody></table><table-wrap-foot><p>*Plus&#x02013;minus values are means &#x000b1; SD. There were no significant differences between the two study groups. Percentages may not total 100 because of rounding.</p><p><sup>&#x02020;</sup>Patients could have multiple causes of DVT or PE.</p><p>DVT, deep-vein thrombosis; PE, pulmonary embolism; SD, standard deviation.</p></table-wrap-foot></table-wrap></sec><sec><title>Treatment and follow-up</title><p>In the standard-therapy group, the median duration of enoxaparin treatment was 9&#x000a0;days (interquartile range, 7&#x02013;12), and the INR at the end of enoxaparin treatment was &#x02265;2.0 in 84.9% of patients. The mean percentage of time during which the INR was in the therapeutic range (2.0&#x02013;3.0) was 52.4%; the corresponding mean percentages for an INR &#x0003e;3.0 and &#x0003c;2.0 were 10.1% and 37.5%, respectively. The mean percentage of time within the therapeutic range ranged from 45.6% (during the third month) to 68.3% (during month 7). In the rivaroxaban group, adherence to therapy was &#x0003e;80% in 93.2% of patients. As an event-driven study, termination upon the required number of events resulted in treatment duration being less than intended in 14 (6.4%) patients in the rivaroxaban group and 11 (5.0%) patients in the standard-therapy group. Four (1.8%) patients in the rivaroxaban group and three (1.4%) patients in the standard-therapy group were lost to follow-up (Table&#x000a0;
<xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Characteristics associated with anticoagulant treatment</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Characteristic</bold></th><th align="center"><bold>Rivaroxaban (n=220)</bold></th><th align="center"><bold>Standard therapy (n=219)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><italic>At least one dose of a study drug received, n (%)</italic><hr/></td><td align="center" valign="bottom">219 (99.5)<hr/></td><td align="center" valign="bottom">218 (99.5)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Intended duration of treatment, n (%)</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;3&#x000a0;months<hr/></td><td align="center" valign="bottom">56 (25.5)<hr/></td><td align="center" valign="bottom">55 (25.1)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;6&#x000a0;months<hr/></td><td align="center" valign="bottom">131 (59.5)<hr/></td><td align="center" valign="bottom">131 (59.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;12&#x000a0;months<hr/></td><td align="center" valign="bottom">33 (15.0)<hr/></td><td align="center" valign="bottom">33 (15.1)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Mean study duration, days</italic><hr/></td><td align="center" valign="bottom">198.5<hr/></td><td align="center" valign="bottom">191.3<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Mean study treatment duration, days<hr/></td><td align="center" valign="bottom">162.2<hr/></td><td align="center" valign="bottom">155.2<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Reasons for premature discontinuation of treatment, n (%)</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Any reason<hr/></td><td align="center" valign="bottom">27 (12.3)<hr/></td><td align="center" valign="bottom">37 (16.9)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Adverse event<hr/></td><td align="center" valign="bottom">14 (6.4)<hr/></td><td align="center" valign="bottom">15 (6.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Consent withdrawn<hr/></td><td align="center" valign="bottom">5 (2.3)<hr/></td><td align="center" valign="bottom">14 (6.4)<hr/></td></tr><tr><td align="left">&#x02003;Loss to follow-up</td><td align="center">4 (1.8)</td><td align="center">3 (1.4)</td></tr></tbody></table></table-wrap></sec><sec><title>Clinical outcomes</title><p>The clinical outcomes are shown in Table&#x000a0;
<xref ref-type="table" rid="T3">3</xref>. The primary efficacy outcome occurred in seven (3.2%) of the 220 patients in the rivaroxaban group compared with seven (3.2%) of the 219 patients in the standard-therapy group, for a hazard ratio of 1.04 (95% confidence interval [CI] 0.36&#x02013;3.0). By day 21, at the end of twice-daily rivaroxaban administration, the primary efficacy outcome had occurred in one (0.5%) patient in the rivaroxaban group and in four (1.8%) patients in the standard-therapy group.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Clinical outcomes</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Outcome</bold></th><th align="center"><bold>Rivaroxaban</bold></th><th align="center"><bold>Standard therapy</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Efficacy</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Intention-to-treat population, n</italic><hr/></td><td align="center" valign="bottom">220<hr/></td><td align="center" valign="bottom">219<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Recurrent VTE, n (%)</italic><hr/></td><td align="center" valign="bottom">7 (3.2)<hr/></td><td align="center" valign="bottom">7 (3.2)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><italic>Type of first recurrent VTE, n</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Fatal PE<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Death in which PE could not be ruled out<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Non-fatal PE<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">2<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Recurrent DVT<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">5<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Net clinical benefit: VTE plus major bleeding, n (%)</italic><hr/></td><td align="center" valign="bottom">7 (3.2)<hr/></td><td align="center" valign="bottom">12 (5.5)<hr/></td></tr><tr><td colspan="3" align="left" valign="bottom"><bold>Safety</bold><hr/></td></tr><tr><td align="left" valign="bottom"><italic>No. of patients, safety population</italic><hr/></td><td align="center" valign="bottom">219<hr/></td><td align="center" valign="bottom">218<hr/></td></tr><tr><td align="left" valign="bottom"><italic>First episode of major or clinically relevant non-major bleeding during treatment, n (%)</italic><hr/></td><td align="center" valign="bottom">13 (5.9)<hr/></td><td align="center" valign="bottom">20 (9.2)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Major bleeding episode, n (%)</italic><hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">5 (2.3)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Fatal<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">2<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Gastrointestinal<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Intracranial<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Other non-fatal episode in a critical site<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Intracranial<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left">&#x02003;&#x02009;Associated with a fall in hemoglobin of &#x02003;&#x02009;&#x02265;2 g/dL, transfusion of &#x02265;2 units, or both</td><td align="center">0</td><td align="center">2</td></tr></tbody></table><table-wrap-foot><p>DVT, deep-vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.</p></table-wrap-foot></table-wrap><p>The principal safety outcome, a first major or clinically relevant non-major bleeding episode, occurred in 13 (5.9%) of the 219 patients in the rivaroxaban group compared with 20 (9.2%) of the 218 patients in the standard-therapy group (hazard ratio, 0.63; 95% CI 0.31&#x02013;1.26; p=0.19) (Figure&#x000a0;
<xref ref-type="fig" rid="F1">1</xref>). Major bleeding occurred in none of the patients in the rivaroxaban group and in five (2.3%) patients in the standard-therapy group. Of these five major bleeding events, two were fatal.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Kaplan&#x02013;Meier curve for cumulative event rate for treatment-emergent major and clinically relevant non-major bleeding.</bold> VKA, vitamin K antagonist.</p></caption><graphic xlink:href="1477-9560-11-25-1"/></fig><p>Among patients who were older than 75 years, major or clinically relevant non-major bleeding occurred in three (9.1%) of the 33 rivaroxaban recipients compared with six (21.4%) of the 28 standard-therapy recipients. In those patients with CrCl &#x0003c;50 mL/min, this outcome occurred in one (5.3%) and six (21.4%) of the 19 and 28 patients, respectively. In frail patients (defined as age &#x0003e;75 years, CrCl &#x0003c;50 mL/min, and/or body weight &#x02264;50 kg), major or clinically relevant non-major bleeding occurred in four (8.9%) of the 45 rivaroxaban patients compared with seven (15.2%) of the 46 standard-therapy patients (Table&#x000a0;
<xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Incidence of major and clinically relevant non-major bleeding according to subgroups</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="center">&#x000a0;</th><th align="center"><bold>Rivaroxaban n/N (%)</bold></th><th align="center"><bold>Standard therapy n/N (%)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><italic>Age, years</italic><hr/></td><td align="center" valign="bottom">&#x0003c;65<hr/></td><td align="center" valign="bottom">7/134 (5.2)<hr/></td><td align="center" valign="bottom">5/133 (3.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">65&#x02013;75<hr/></td><td align="center" valign="bottom">3/52 (5.8)<hr/></td><td align="center" valign="bottom">9/57 (15.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x0003e;75<hr/></td><td align="center" valign="bottom">3/33 (9.1)<hr/></td><td align="center" valign="bottom">6/28 (21.4)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Creatinine clearance, mL/min</italic><hr/></td><td align="center" valign="bottom">&#x02265;80<hr/></td><td align="center" valign="bottom">8/117 (6.8)<hr/></td><td align="center" valign="bottom">4/116 (3.4)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">50&#x02013;&#x0003c;80<hr/></td><td align="center" valign="bottom">3/75 (4.0)<hr/></td><td align="center" valign="bottom">10/72 (13.9)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x0003c;50<hr/></td><td align="center" valign="bottom">1/19 (5.3)<hr/></td><td align="center" valign="bottom">6/28 (21.4)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Body weight, kg</italic><hr/></td><td align="center" valign="bottom">&#x02264;50<hr/></td><td align="center" valign="bottom">0/3<hr/></td><td align="center" valign="bottom">2/11 (18.2)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x0003e;50&#x02013;70<hr/></td><td align="center" valign="bottom">9/134 (6.7)<hr/></td><td align="center" valign="bottom">14/134 (10.4)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x0003e;70&#x02013;90<hr/></td><td align="center" valign="bottom">3/79 (3.8)<hr/></td><td align="center" valign="bottom">4/69 (5.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x0003e;90<hr/></td><td align="center" valign="bottom">0/1<hr/></td><td align="center" valign="bottom">0/4<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Fragility*</italic><hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">9/174 (5.2)<hr/></td><td align="center" valign="bottom">13/172 (7.6)<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="center">Yes</td><td align="center">4/45 (8.9)</td><td align="center">7/46 (15.2)</td></tr></tbody></table><table-wrap-foot><p>*Defined as age &#x0003e;75 years, creatinine clearance &#x0003c;50 mL/min, and/or body weight &#x02264;50 kg.</p></table-wrap-foot></table-wrap></sec><sec><title>Other outcomes</title><p>Net clinical benefit (i.e. the combination of the primary efficacy outcome and major bleeding) was more favorable in the rivaroxaban group: the net clinical benefit outcome occurred in seven (3.2%) of the 220 rivaroxaban recipients versus 12 (5.5%) of the 219 standard-therapy recipients, for a hazard ratio of 0.59 (95% CI 0.23&#x02013;1.51) (Table&#x000a0;
<xref ref-type="table" rid="T3">3</xref>). Two (0.9%) patients in the rivaroxaban group developed another vascular outcome (both ischemic strokes), compared with two (0.9%) patients in the standard-therapy group (ischemic stroke and myocardial infarction). Six (2.7%) patients in the rivaroxaban group and 11 (5.0%) patients in the standard-therapy group died during the study.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This analysis of data from Chinese patients included in the EINSTEIN DVT and EINSTEIN PE studies
[<xref ref-type="bibr" rid="B11">11</xref>] showed similar point estimates of relative efficacy and safety of oral rivaroxaban alone compared with standard-therapy for the treatment of symptomatic DVT and/or PE, consistent with results observed in the global studies.</p><p>There is an indication that VKAs are dosed more cautiously in China; the percentage of time spent with INR value &#x0003c;2.0 was higher compared with global studies (37% vs. 22%) and the percentage of time spent in the therapeutic range was lower (52% vs. 62%). Interestingly, the incidence of major or clinically relevant non-major bleeding was similar in China compared with the global study population (9.2% vs. 10.0%) for standard-therapy recipients, whereas this incidence tended to be lower (5.9% vs. 9.4%) for rivaroxaban recipients
[<xref ref-type="bibr" rid="B11">11</xref>]. This confirms the favorable safety profile of oral rivaroxaban (compared with standard therapy for the treatment of VTE) in Chinese patients.</p><p>With regard to efficacy, recurrent events occurred in 3.2% of patients in the rivaroxaban group and 3.2% of those in the standard-therapy group. These rates were slightly higher than in the global study (2.1% and 2.3% for rivaroxaban and standard therapy, respectively).</p><p>There has been a traditional perception that, because of ethnic differences, Chinese people do not develop VTE at the same rate as Caucasians. However, although incidences of DVT and PE in the general Chinese population are unknown, some published studies suggest that the incidence of VTE in hospitalized medically ill patients is similar in these ethnic groups
[<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Regardless of the rates of VTE, the standard of care in China is the same as the standard therapy used in the EINSTEIN program, i.e. low-molecular-weight heparin overlapping with and followed by an adjusted-dose VKA. Consistent with the global data, rivaroxaban showed similar efficacy to standard therapy in the Chinese patient population, with a tendency towards an improved safety profile, as demonstrated by the lower incidence of major and clinically relevant non-major bleeding complications, a result that was also observed in frail patients.</p><p>A number of studies have shown that Chinese patients have lower warfarin requirements to achieve a target INR range, indicating that Chinese patients may have an increased sensitivity to the anticoagulant effect of VKAs compared with Caucasians
[<xref ref-type="bibr" rid="B14">14</xref>]. This sensitivity to warfarin has not been definitively linked to higher rates of bleeding in Chinese patients, and little is known about the optimal intensity of anticoagulation. The few studies that have assessed whether bleeding on anticoagulation is similar in Chinese and Caucasian patients have shown mixed results, were retrospective, and included small numbers of patients
[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In the global studies, there is an indication that Chinese doctors give VKAs in dosages aimed to obtain a slightly lower INR. This did not affect the more favorable bleeding profile of rivaroxaban.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In summary, the results of this analysis of the patients included in China in the EINSTEIN DVT and EINSTEIN PE trials show that the performance of rivaroxaban was consistent with that observed in the global population, with a similar efficacy and a better bleeding profile to standard therapy of enoxaparin overlapping with and followed by a VKA. The data indicate that oral rivaroxaban provides a new, improved option for the treatment of DVT and PE in Chinese patients.</p></sec><sec><title>Abbreviations</title><p>CI: Confidence interval; CrCl: Creatinine clearance; CYP: Cytochrome P450; DVT: Deep-vein thrombosis; INR: International normalized ratio; PE: Pulmonary embolism; VKA: Vitamin K antagonist; VTE: Venous thromboembolism.</p></sec><sec><title>Competing interests</title><p>MHP: has acted as a consultant for Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, Daiichi Sankyo, Leo Pharma, ThromboGenics, and Pfizer. ILM, AFP, KM, and AWAL are employees of Bayer Pharma AG. The other authors have no competing interests to declare.</p></sec><sec><title>Authors&#x02019; contributions</title><p>YW, CW, ILM, MHP, and AWAL interpreted the data and were involved in the initial drafting and revising of the manuscript; AFP and KM performed the statistical analyses and contributed to the discussions of the data. All authors contributed to the execution of the study and discussed the study results. All authors provided final approval for publication of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>The Chinese EINSTEIN Investigators.</bold> *Investigator included in the author list was involved in developing the manuscript draft.</p></caption><media xlink:href="1477-9560-11-25-S1.docx"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The authors would like to thank the following investigators for recognition of their support in study planning locally: Yuanhua Yang and Zhenyu Shi. The authors would like to thank David Whitford, who provided editorial support with funding from Bayer HealthCare Pharmaceuticals and Janssen Scientific Affairs, LLC.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Silverstein</surname><given-names>MD</given-names></name><name><surname>Heit</surname><given-names>JA</given-names></name><name><surname>Mohr</surname><given-names>DN</given-names></name><name><surname>Petterson</surname><given-names>TM</given-names></name><name><surname>O'Fallon</surname><given-names>WM</given-names></name><name><surname>Melton</surname><given-names>LJ</given-names><suffix>III</suffix></name><article-title>Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study</article-title><source>Arch Intern Med</source><year>1998</year><volume>11</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1001/archinte.158.6.585</pub-id><pub-id pub-id-type="pmid">9521222</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Oger</surname><given-names>E</given-names></name><article-title>Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP study group. Groupe d'Etude de la thrombose de Bretagne occidentale</article-title><source>Thromb Haemost</source><year>2000</year><volume>11</volume><fpage>657</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">10823257</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Douketis</surname><given-names>JD</given-names></name><name><surname>Kearon</surname><given-names>C</given-names></name><name><surname>Bates</surname><given-names>S</given-names></name><name><surname>Duku</surname><given-names>EK</given-names></name><name><surname>Ginsberg</surname><given-names>JS</given-names></name><article-title>Risk of fatal pulmonary embolism in patients with treated venous thromboembolism</article-title><source>JAMA</source><year>1998</year><volume>11</volume><fpage>458</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1001/jama.279.6.458</pub-id><pub-id pub-id-type="pmid">9466640</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Barritt</surname><given-names>DW</given-names></name><name><surname>Jordan</surname><given-names>SC</given-names></name><article-title>Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial</article-title><source>Lancet</source><year>1960</year><volume>11</volume><fpage>1309</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">13797091</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Kearon</surname><given-names>C</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Comerota</surname><given-names>AJ</given-names></name><name><surname>Prandoni</surname><given-names>P</given-names></name><name><surname>Bounameaux</surname><given-names>H</given-names></name><name><surname>Goldhaber</surname><given-names>SZ</given-names></name><name><surname>Nelson</surname><given-names>ME</given-names></name><name><surname>Wells</surname><given-names>PS</given-names></name><name><surname>Gould</surname><given-names>MK</given-names></name><name><surname>Dentali</surname><given-names>F</given-names></name><name><surname>Crowther</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>SR</given-names></name><article-title>Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines</article-title><source>Chest</source><year>2012</year><volume>11</volume><fpage>e419S</fpage><lpage>e494S</lpage><pub-id pub-id-type="pmid">22315268</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Perzborn</surname><given-names>E</given-names></name><name><surname>Roehrig</surname><given-names>S</given-names></name><name><surname>Straub</surname><given-names>A</given-names></name><name><surname>Kubitza</surname><given-names>D</given-names></name><name><surname>Mueck</surname><given-names>W</given-names></name><name><surname>Laux</surname><given-names>V</given-names></name><article-title>Rivaroxaban: a new oral factor Xa inhibitor</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2010</year><volume>11</volume><fpage>376</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.110.202978</pub-id><pub-id pub-id-type="pmid">20139357</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Mueck</surname><given-names>W</given-names></name><name><surname>Kubitza</surname><given-names>D</given-names></name><name><surname>Bauer</surname><given-names>RJ</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><article-title>Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects</article-title><source>Thromb Haemost</source><year>2010</year><volume>11</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">20062915</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><collab>The EINSTEIN Investigators</collab><article-title>Oral rivaroxaban for symptomatic venous thromboembolism</article-title><source>N Engl J Med</source><year>2010</year><volume>11</volume><fpage>2499</fpage><lpage>2510</lpage><pub-id pub-id-type="pmid">21128814</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><collab>The EINSTEIN&#x02013;PE Investigators</collab><article-title>Oral rivaroxaban for the treatment of symptomatic pulmonary embolism</article-title><source>N Engl J Med</source><year>2012</year><volume>11</volume><fpage>1287</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">22449293</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Prins</surname><given-names>MH</given-names></name><name><surname>Lensing</surname><given-names>AWA</given-names></name><article-title>Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism</article-title><source>Thromb J</source><year>2013</year><volume>11</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/1477-9560-11-13</pub-id><pub-id pub-id-type="pmid">23829521</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Prins</surname><given-names>MH</given-names></name><name><surname>Lensing</surname><given-names>AWA</given-names></name><name><surname>Bauersachs</surname><given-names>R</given-names></name><name><surname>van Bellen</surname><given-names>B</given-names></name><name><surname>Bounameaux</surname><given-names>H</given-names></name><name><surname>Brighton</surname><given-names>TA</given-names></name><name><surname>Cohen</surname><given-names>AT</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name><name><surname>Decousus</surname><given-names>H</given-names></name><name><surname>Raskob</surname><given-names>GE</given-names></name><name><surname>Berkowitz</surname><given-names>SD</given-names></name><name><surname>Wells</surname><given-names>PS</given-names></name><collab>on behalf of the EINSTEIN Investigators</collab><article-title>Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies</article-title><source>Thromb J</source><year>2013</year><volume>11</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/1477-9560-11-21</pub-id><pub-id pub-id-type="pmid">24053656</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Leung</surname><given-names>V</given-names></name><name><surname>Leung</surname><given-names>V</given-names></name><name><surname>Lui</surname><given-names>W</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>RS</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><article-title>Incidence of deep vein thrombosis in hospitalized Chinese medical patients is similar to that in Western populations</article-title><source>Thromb Res</source><year>2006</year><volume>11</volume><fpage>763</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2005.12.014</pub-id><pub-id pub-id-type="pmid">16460786</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>YT</given-names></name><name><surname>Choy</surname><given-names>YF</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><name><surname>Yeung</surname><given-names>PK</given-names></name><name><surname>Ng</surname><given-names>KL</given-names></name><name><surname>Tsang</surname><given-names>LS</given-names></name><name><surname>Wong</surname><given-names>RS</given-names></name><article-title>Incidence of deep vein thrombosis in hospitalized Chinese medical patients and the impact of DVT prophylaxis</article-title><source>Thrombosis</source><year>2011</year><volume>11</volume><fpage>629383</fpage><pub-id pub-id-type="pmid">22084666</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>You</surname><given-names>JH</given-names></name><name><surname>Chan</surname><given-names>FW</given-names></name><name><surname>Wong</surname><given-names>RS</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><article-title>Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>11</volume><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02361.x</pub-id><pub-id pub-id-type="pmid">15842557</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>TY</given-names></name><name><surname>Miu</surname><given-names>KY</given-names></name><article-title>Hemorrhagic complications of anticoagulant therapy in Chinese patients</article-title><source>J Chin Med Assoc</source><year>2004</year><volume>11</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15146899</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Chenhsu</surname><given-names>RY</given-names></name><name><surname>Chiang</surname><given-names>SC</given-names></name><name><surname>Chou</surname><given-names>MH</given-names></name><name><surname>Lin</surname><given-names>MF</given-names></name><article-title>Long-term treatment with warfarin in Chinese population</article-title><source>Ann Pharmacother</source><year>2000</year><volume>11</volume><fpage>1395</fpage><lpage>1401</lpage><pub-id pub-id-type="pmid">11144695</pub-id></mixed-citation></ref></ref-list></back></article>